Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Could octreotide become a first‑line systemic option in VWD patients with angiodysplasia‑related GI bleeding?
Great talk by Sophie Susen at the EHA meeting in Florence on angiodysplasia‑related GI bleeding and the implications of the OCEAN trial for VWD.
OCEAN trial:
- Multicenter RCT in 62 patients with transfusion‑dependent angiodysplasia‑related anemia, Octreotide LAR 40 mg q4w vs standard care.
- About 50% reduction in transfusion requirements (11.0 vs 21.2 units), alongside fewer endoscopic procedures and hospitalizations, with a generally favourable safety profile.
What octreotide actually does
Octreotide, a long‑acting somatostatin analogue, reduces splanchnic blood flow and portal pressure, improves platelet aggregation, and exerts anti‑angiogenic effects via inhibition of VEGF and other growth factors.
This mechanistic profile makes it particularly attractive for chronic bleeding from GI angiodysplasia.
What this could mean for VWD
Even though VWD patients were not included in OCEAN, these robust data provide the best evidence we currently have for systemic therapy in angiodysplasia‑related bleeding and strongly support octreotide as a potential first‑line systemic option in this setting.
Case reports and small series in VWD already suggest benefit, but dedicated prospective trials in VWD with angiodysplasia are urgently needed to define efficacy, safety, and optimal positioning in future treatment algorithms.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event